A phase I/II trial of etoposide and cisplatin in extensive small cell lung cancer. A cancer and Leukemia Group B study

Lung Cancer

Volumn 15, Issue 2, 1996, Pages 215-223

  Mitchell, Edith P ^a,h   Perry, Michael C ^a   Luikart, Sharon D ^b   Cirrincione, Constance T ^d   Van Echo, David A ^c   Herndon II, James E ^d   Maurer, L Herbert ^e   Clamon, Gerald ^f   Green, Mark R ^g  

^a UNIVERSITY OF MISSOURI   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^d CALGB Statistical Center   (United States)

^e DARTMOUTH MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF IOWA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Cisplatin; Dose intensity; Etoposide; Small cell lung cancer

Indexed keywords

CISPLATIN; ETOPOSIDE;

ALOPECIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOXICITY; FEMALE; HUMAN; LEUKOPENIA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0030249649     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/0169-5002(95)00585-4     Document Type: Article

References (36)

1. [1] Arnold AM. General review. Podophyllotoxin derivative VP-16-213. Cancer Chemother Pharmacol 1979; 3: 71-80.
2. [2] Carney DN, Grogan L, Smit EF et al. Single-agent etoposide for elderly small cell lung cancer patients. Semin Oncol 1990; 17 Suppl 2: 49-53.
3. [3] Cavalli F, Sontag RW, Jungi F et al. VP-16-213 monotherapy for remission induction of small cell lung cancer: A randomized trial using three dosage schedules. Cancer Treat Rep 1978; 62: 473-475.
4. [4] Dally MB, Harper P, Smyth JF et at. Epipodophyllotoxin (VP-16-213) in small cell carcinoma of the bronchus resistant to initial combined chemotherapy. Br J Dis Chest 1980; 74: 312.
5. [5] Dombernowsky P, Sorenson S, Aisner J et al, Cis-dichloro-diamino-platinum (II) in small cell anaplastic bronchogenic carcinoma: A phase II study. Cancer Treat Rep 1979; 63: 543-545.
6. [6] Drewinko B, Green C, Loo TL. Combination chemotherapy in vitro with cis-dichlorodiammine-platinum (II). Cancer Treat Rep 1976; 60: 1619-1625.
7. [7] Evans WK, Feld R, Murray N et al: Superiority of alternating non-cross resistant chemotherapy in extensive stage small cell lung cancer. Ann Intern Med 1987; 107: 451-458.
8. [8] Evans WK, Feld R, Osoba D et al. VP16 alone and in combination with cisplatin in previously treated patients with small cell lung cancer. Cancer 1984; 53: 1461-1466.
9. [9] Evans WK, Osoba D, Feld R et al. Etoposide (VP-16) and cisplatin: an effective treatment for relapse of small cell lung cancer. J Clin Oncol 1985; 3: 65-71.
10. [10] Evans WK, Shepherd FA, Feld R et al. VP-16 and cisplatin as first-line therapy for small cell lung cancer. J Clin Oncol 1985; 3: 1471-1477.
11. [11] Feld R, Evans WK, Coy P et al. Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung. J Clin Oncol 1987; 5: 1401-1409.
12. [12] Fukuoka M, Furuse K, Saijo N et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens. J Natl Cancer Inst 1991; 83: 855-861.
13. [13] Goldhirsch A, Joss R, Cavalli F et al. Etoposide as a single agent and in combination chemotherapy of bronchogenic carcinoma. Cancer Treat Rev 1982; 9 Suppl A: 85-90.
14. 1-Dimethyl epipodophyllotoxin 9-4, 6-0-ethylidene-beta-D-glucopyranoside). Cancer 1977; 40: 633-637.
15. [15] Ihde DC, Mulshine JL, Kramer BS et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol 1994; 12: 2022-2034.
16. [16] Issell BF, Einhorn LH, Comis RL et al. Multicenter Phase II trial of etoposide in previously treated small cell carcinoma of the lung. Cancer Treat Rep 1985; 69: 127-128.
17. [17] Jungi WF, Cavalli F, Alberto P et al. Etoposide (VP-16-213): A very active drug in small cell lung cancer. The Swiss experience. Proc Third World Conf Lung Cancer 1982; 173 (Abstr 243).
18. [18] Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
19. [19] Kim RN, McDonald DB. The combination of VP-16-213 and cisplatinum in the treatment of small cell carcinoma of the lung. Proc Am Soc Clin Oncol 1982; 1: 141 (Abstr 547).
20. [20] Lopez JA, Mann J, Grapski, Nassif E, Vannicola P, Krikorian JG, Finkel H. Etoposide and cisplatin salvage chemotherapy for small cell lung cancer. Cancer Treat Rep 1985; 69: 369-371.
21. [21] Luikart SD, Goutsou M, Mitchell ED et al. Phase I/II trial of etoposide and carboplatin in extensive small-cell lung cancer. Am J Clin Oncol 1993; 16: 127-131.
22. [23] Mayzei T, Marino C, Nozzoli F et al. Cisplatin and etoposide in the treatment of bronchogenic carcinoma. Chemioterapia 1984; 3: 16-18.
23. [24] Mead GM, Thompson J, Sweeten JW et al. Extensive stage small cell carcinoma of the bronchus: a randomized study of etoposide given orally by one-day or five-day schedule together with intravenous adriamycin and cyclophosphamide. Cancer Chemother Pharmacol 1987; 19: 172-174.
24. [25] Porter LL, Johnson DH, Hainsworth JD et al. Cisplatin and etoposide combination chemotherapy for refractory small cell carcinoma of the lung. Cancer Treat Rep 1985; 69: 479-481.
25. [26] Rossof H, Bearden JD III, Coltman CA Jr. Phase II evaluation of cis-diammine-dichloroplatinum (II) in lung cancer. Cancer Treat Rep 1976; 60; 1979-1980.
26. [27] Schabel FM, Trader MW, Laster WK et al. Cis-Dichlorodiammine platinum (II): Combination chemotherapy and cross resistance studies with tumors of mice. Cancer Treat Rep 1979; 63: 1459-1473.
27. [28] Seifter EJ, Ihde DE. Therapy of small cell lung cancer: a perspective on two decades of clinical research. Semin Oncol 1988; 15: 278-299.
28. [29] Sierocki JS, Hilaris BS, Hopfan S et al. Cis-Dichlorodiamminoplatinum (II) and VP-16-213. An active induction regimen for small cell carcinoma of the lung. Cancer Treat Rep 1979; 63: 1593-1597.
29. [30] Slevin ML, Clark PI, Joel S et al. A randomized trial to examine the effect of schedule on the activity of etoposide in small cell lung cancer. J Clin Oncol 1989; 7: 1333-1340.
30. [31] Souhami RL. Small cell lung cancer: new approaches to treatment. Clin Oncol 1985; 4: 177-189.
31. [32] Souhami RL, Geddes DM, Spiro SG et al. Radiotherapy in small cell cancer of the lung treated with combination chemotherapy: a controlled trial. Br Med J 1984; 288: 1643-1646.
32. [33] Tempero M, Kessinger A, Lemon HM. VP-16-213 therapy in patients with small cell carcinoma of the lung after failure on combination chemotherapy. Cancer Clin Trials 1981; 4: 155-157.
33. [34] Tucker RD, Ferguson A, Van Wyck C et al. Chemotherapy of small cell carcinoma of the lung with VP-16-213. Cancer 1978; 41: 1710-1714.
34. [35] Von Hoff DD, Elson D. Clinical results with cisplatin in lung cancer. In: Prestayko AW, Crooke S, Carter SK, editors. Cisplatin current status and new developments, Vol. I. Orlando, FL: Academic Press, 1980; 445-458.
35. [37] Wolff M, Havemann K, Holle R et al. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small cell lung cancer: a multicenter German randomized trial. J Clin Oncol 1987; 5: 1880-1889.
36. [38] Woods RL, Levine JA. Chemotherapy for small cell lung cancer (SCLC): a randomized study of maintenance therapy with cyclophosphamide, Adriamycin and vincristine (CAV) after remission induction with cis-platinum (Cis, DDP), VP-16-213, and radiotherapy. Proc Am Soc Clin Oncol 1984; 3: 214 (Abstr C-836).